Kangpu Biopharma Secures Nearly RMB 100 Million in Pre-B Financing Led by Guozhong Venture Capital, Furong Investment, and Northern Light Venture Capital

Recently, Kangpu Biomedical Technology (Shanghai) Co., Ltd. (hereinafter referred to as “Kangpu Biomedical”) completed a Pre-B financing round of nearly RMB 100 million. This round was jointly invested by Shenzhen Guozhong Venture Capital Management Co., Ltd. (hereinafter referred to as “Guozhong VC”) and Shanghai Furong Investment Co., Ltd. (hereinafter referred to as “Furong Investment”), with existing investor Northern Light Venture Capital continuing to participate in the investment.

Headquartered in the Zhangjiang Hi-Tech Park in Shanghai, Kangpu Biomedical is a clinical-stage innovative biopharmaceutical company. The company boasts a robust team of senior experts and operational professionals with international perspectives and extensive industry experience in innovative drug development. Driven by innovation and focusing on therapeutic areas such as cancer, autoimmune diseases, and inflammation, Kangpu Biomedical leverages its proprietary technologies—including internationally leading next-generation protein ubiquitination and degradation platforms and the X-Synergy® drug combination technology platform—to develop novel Class I small-molecule targeted immunomodulatory drugs with global independent intellectual property rights for the worldwide market.

Currently, the company has established a robust R&D pipeline in therapeutic areas including prostate cancer, myelodysplastic syndromes, diffuse large B-cell lymphoma, multiple myeloma, mantle cell lymphoma, indolent lymphomas, systemic lupus erythematosus, psoriasis, and arthritis. This pipeline features multiple innovative drug candidates with First-in-Class or Best-in-Class potential, two of which have entered Phase I clinical trials in the United States.

Dr. Ge Chuansheng, Founder, Chairman, and CEO of Kangpu Biomedical, stated, “We are honored to have Guozhong Venture Capital and Furong Investment join this round of financing, and we thank our existing investor, Northern Light Venture Capital, for its continued support. The proceeds from this round will accelerate the clinical trials of our pipeline projects and expedite the preclinical development of other innovative drug candidates. We look forward to working closely with all investors to provide more effective treatment options for patients worldwide.”

Guozhong Venture Capital stated: “Overcoming drug resistance to existing medications, significantly enhancing drug efficacy, and ensuring the safety of long-term medication have become key directions in new drug development. Kangpu Biomedical has designed and developed a series of novel small-molecule immunomodulatory targeted drugs based on protein ubiquitination and its degradation mechanisms, providing fresh approaches to achieving these goals. The preclinical research data from its product pipeline are impressive, and the results of subsequent clinical trials are highly anticipated. Guozhong Venture Capital will fully leverage the advantages of being a national-level fund to support the rapid development of Kangpu Biomedical, and we are confident in this endeavor.”

Furong Investment stated, “The rising global incidence of advanced prostate cancer, systemic lupus erythematosus, and various hematologic malignancies—particularly in China—represents a significant unmet clinical need. Leveraging the novel mechanism of protein ubiquitination and degradation, Kangpu Biomedical is developing innovative drugs with superior efficacy and enhanced safety profiles, bringing hope to patients who have previously exhausted treatment options. We are delighted to collaborate with an exceptional team led by Dr. Ge Chuansheng, whose extensive experience in domestic and international research and clinical development will accelerate the progress of Kangpu’s drug pipeline. Our shared goal is to deliver first-in-class, Chinese-originated innovative medicines of international caliber to patients in urgent need as soon as possible.”

Kangpu Biomedical R&D Pipeline

Guozhong Venture Capital is a private equity investment firm specializing in the entrusted management of venture capital. It currently serves as the manager of the first physical fund under the National SME Development Fund, namely the SME Development Fund (Shenzhen Limited Partnership), with a size of RMB 6 billion. Guozhong Venture Capital advocates an investment philosophy that prioritizes research and integrates investment with research. Guided by in-depth industry chain analysis, the firm focuses on investment opportunities in strategic emerging industries, with particular emphasis on outstanding enterprises in three key sectors: technological innovation, biopharmaceuticals and healthcare, and TMT (Technology, Media, and Telecom).

Shanghai Furong Investment Co., Ltd. is a technology finance and innovation entrepreneurship platform initiated by the Ningbo Research Institute of Fudan University. Leveraging its robust advantages in talent, scientific research, academia, and clinical resources, Furong Investment promotes the industrialization of scientific and technological achievements and supports high-level talent in innovation and entrepreneurship. It actively serves national innovation-driven development strategies, including the integrated development of the Yangtze River Delta region and Shanghai’s initiative to build a globally influential science and technology innovation center.The Shanghai Furong Qingyun Fund, established by Shanghai Furong Investment Co., Ltd., is a professional investment fund focused on the industrialization of scientific and technological achievements. The fund targets three major industry clusters: life and health, intelligent manufacturing, and green technology. It prioritizes early- to mid-stage startups at the scientific frontier and industrial forefront, operating and investing in accordance with market-oriented, professional, and international standards.

Northern Light Venture Capital was founded by Mr. Deng Feng in 2005. It is a venture capital firm dedicated to “empowering world-class entrepreneurs and nurturing world-class Chinese enterprises.” Currently, it manages five U.S. dollar funds and five RMB funds, with assets under management exceeding RMB 30 billion. The firm has long focused on investing in early-stage, technology-driven innovative companies. To date, Northern Light has invested in more than 200 outstanding companies in the TMT, advanced technology, and healthcare sectors, including Meituan, ThunderSoft, ChineseAll, BGI Genomics, Blueport Interactive, Spreadtrum Communications, APUS, Ocean Music, Hanting Hotel, GigaDevice, Dianrong, CITIC Pharmaceutical, and VIPKID.